Afficher la notice abrégée

Safety and Preliminary Efficacy Findings from a Phase 2A Randomized, Double-Blind, Placebo-Controlled Trial of Setanaxib in Patients with Alport Syndrome SA-OR082

dc.contributor.authorEsteban de la Rosa, Rafael José 
dc.date.accessioned2025-12-30T17:13:58Z
dc.date.available2025-12-30T17:13:58Z
dc.date.issued2025-11
dc.identifier.otherhttps://journals.lww.com/jasn/toc/2025/10001
dc.identifier.urihttps://hdl.handle.net/10481/109150
dc.language.isoenges_ES
dc.rightsCreative Commons Attribution-NonCommercial-NoDerivs 3.0 Licenseen_EN
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/3.0/en_EN
dc.titleSafety and Preliminary Efficacy Findings from a Phase 2A Randomized, Double-Blind, Placebo-Controlled Trial of Setanaxib in Patients with Alport Syndrome SA-OR082es_ES
dc.typejournal articlees_ES
dc.rights.accessRightsembargoed accesses_ES
dc.identifier.doi10.1681/ASN.20253w14s1fa
dc.identifier.doi10.1681/ASN.20253w14s1fa
dc.type.hasVersionAOes_ES


Fichier(s) constituant ce document

[jpg]
Nom:
IMG_9574.jpeg
Taille:
365.5Ko
Format:
Image JPEG
[jpg]
Nom:
IMG_9763.jpeg
Taille:
377.8Ko
Format:
Image JPEG

Ce document figure dans la(les) collection(s) suivante(s)

Afficher la notice abrégée

Creative Commons Attribution-NonCommercial-NoDerivs 3.0 License
Excepté là où spécifié autrement, la license de ce document est décrite en tant que Creative Commons Attribution-NonCommercial-NoDerivs 3.0 License